ABSTRACT
Introduction Pathogenic mutations in STXBP1 and SLC6A1 can cause developmental delay and epilepsy. 4-phenylbutyrate (4PB), a drug used for urea cycle disorders, rescues dysfunction in pre-clinical models for both genes, suggesting an opportunity for drug repurposing.
Methods We conducted a single-treatment group, multiple-dose, open-label study of 4PB (as glycerol phenylbutyrate) in children with pathogenic STXBP1 and SLC6A1 mutations at two centers (NCT04937062). Enrolled participants were monitored for 4 weeks (baseline) then received 4PB for 10 weeks, with an option for extended use. Endpoints were safety and tolerability (primary) as well as seizure burden, EEG abnormalities, quality of life, development, behavior, and sleep (exploratory). We report safety, tolerability, EEG, and seizure outcomes.
Results We enrolled 20 children (10 STXBP1, 10 SLC6A1; median age 5 years, absolute range 4 months to 11 years; 14 males; all White, 2 Hispanic). There were six serious adverse events, one attributed to 4PB (hospitalization for metabolic acidosis). Other common adverse events included a honey-like odor, sedation, and anorexia. After one participant initially withdrew for metabolic acidosis (SLC6A1), 18 of the 19 remaining participants opted for extended use. Of these 18, 17 (94%) continued 4PB within 10% of the target dose (11.2 mL/m^2/day) at the last clinical visit (2-3 years). At baseline, every child had abnormal EEG findings (seizures, paroxysmal or generalized slowing, or epileptiform discharges). For STXBP1, EEG improvements after one year of 4PB include (1) six with EEG seizures before 4PB versus two after and (2) nine with epileptiform discharges on initial EEGs versus four after. For SLC6A1, there was no clear pattern of EEG evolution. After 10 weeks of 4PB, seizures (or spells) were reduced in STXBP1 for six (60%), and in SLC6A1 for seven (70%). Seizure outcomes at the last visit were as follows. For STXBP1, three children were seizure-free and six had seizures daily to monthly; for SLC6A1, eight had sustained reduction in seizures, typically with seizure freedom and brief relapses that resolved after weight adjustment of the 4PB dose.
Conclusion This case series found 4PB was safe and well-tolerated and reduced seizures for STXBP1 and SLC6A1 disorders.
Question Is 4-phenylbutyrate (4PB; a drug used for urea cycle disorders) safe, tolerable, and effective for people with developmental delay and seizures due to mutations in STXBP1 or SLC6A1?
Findings In a single-treatment group, multiple-dose, open-label study of 4PB at two centers, treatment of 20 children (10 STXBP1 and 10 SLC6A1) with 4PB (as glycerol phenylbutyrate) was safe (no new side effects) and well tolerated (19 enrolled in extended use). For both disorders, seizures improved in the short term (6 STXBP and 7 SLC6A1 with fewer seizures after 6 weeks) and long term (3 STXBP1 and 8 SLC6A1 with sustained seizure reduction after 2-3 years of use).
Meaning 4PB is a safe and well-tolerated repurposed drug that may improve seizure control in STXBP1 and SLC6A1.
Competing Interest Statement
This investigator-initiated study was funded by multiple sources, including for-profit pharmaceutical companies (Horizon Therapeutics, now Amgen), non-profit caregiver-led advocacy groups (STXBP1 Foundation, SLC6A1 Connect), academic medical centers (Weill Cornell Medicine and Penn Medicine via the Orphan Disease Center), and private philanthropy (Morris and Alma Schapiro Fund, Clara Inspired). Dr. Grinspan (corresponding author) currently receives research funding from Weill Cornell Medicine, NIH/NINDS (R01NS130113), Amgen, Harmony Biosciences, SLC6A1 Connect, STXBP1 Foundation, the Morris and Alma Schapiro Fund, the Jain Foundation, and the D'Addario Foundation. Dr. Grinspan has conducted paid consulting work for Capsida Therapeutics, Mahzi Therapeutics, Encoded Therapeutics, and Neurvati Neurosciences. Dr. Burre receives research funding from NIH/NINDS (R01NS113960, R01NS121077, R01AG083949, RF1NS126342, R01NS113960), and is a member of the scientific advisory board for the SNAP-25 foundation and the VAMP2 foundation. Dr. Cross receives research support from Amgen, STXBP1 Foundation, and SLC6A1 Connect. Dr. Ross receives research support from the NIH (R01NS105477, U54NS117170, OT2OD037643). Dr. Kang receives research support from NIH/NINDS (R01NS121718) and SLC6A1 Connect. Dr. Miele consults for Biogen Inc., Capsida Biotherapeutics, and Encoded Therapeutics. She receives research funding from the STXBP1 Foundation. Dr. Demarest has consulted for Biomarin, Neurogene, Marinus, Tysha, Ultragenyx, UCB, Capsida, Encoded, Longboard, Mahzi Therapeutics, and Ovid Therapeutics. He has funding from the NIH, Project 8P, and Mila's Miracle Foundation. He also serves on advisory boards for the non-profit foundations Rare X, SLC6A1 Connect, Project 8P, Ring14 USA, FamilieSCN2A, and N of 1 Collaborative.
Clinical Trial
NCT04937062
Funding Statement
This investigator-initiated study received funding from for-profit pharmaceutical companies (Horizon Therapeutics, now Amgen), non-profit caregiver-led advocacy groups (STXBP1 Foundation, SLC6A1 Connect), academic medical centers (Weill Cornell Medicine and Penn Medicine via the Orphan Disease Center), and private philanthropy (Morris and Alma Schapiro Fund, Clara Inspired). Enrollment criteria were selected with input from the caregiver-led advocacy groups. The study team designed the study, selected participants, collected and managed the data, performed the analyses, and wrote the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRBs of both Weill Cornell Medicine and Children's Hospital Colorado gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Fixed typos in the abstract as displayed on the medrxiv website
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
